Amgen (AMGN)
Health Care · biotechnology · NASDAQ
Amgen is a leading biotechnology firm dedicated to developing innovative human therapeutics to address critical unmet needs in areas like oncology, inflammation, and cardiovascular disease.
What Amgen does
Amgen is a global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics for serious illnesses. Its diverse portfolio includes treatments for inflammation, oncology/hematology, bone health, cardiovascular disease, and nephrology. The company is also active in the development of biosimilars and innovative small molecule and biologic therapies.
Themes: oncology, inflammation / immunology, cardiovascular health, bone health / osteoporosis, biosimilars, drug pricing / policy reform, Medicare / Medicaid reimbursement
Fundamentals
- Price$439.33 as of 2026-08-21 close
- Market cap$237.5B as of 2026-08-21
- 1-year return+48.5% 2025-08-21 close $295.76 → 2026-08-21 close $439.33
- P/E25.84 as of 2026-08-24
- Net margin+22.9% as of 2026-08-24
- Gross margin+74.3% as of 2026-08-24
- ROE+89.3% as of 2026-08-24
- Debt / equity4.90 as of 2026-08-24
- Revenue growth (YoY)+9.1% as of 2026-08-24
- Revenue CAGR (3y)+11.8% SEC XBRL
- Beta0.41 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +3.2%; at least 5 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How AMGN compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldtop 25% 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
AMGN is in the Health Care Long-term Top 10.
Health Care Long-term Top 10 — since 18 Aug 2026
Long-term score
66.8 #70 of 987 scored · #2 of 57 in Health Care
Long-term trend 88th (a strong uptrend, with buyers in control) and profitability 87th (return on equity 89.3%, operating margin 30.3%); weakest is valuation (27th, price to book 20.3, price to earnings 27.3).
Short-term score
53.2 #585 of 1,704 scored · #108 of 240 in Health Care
Trend 86th: a strong uptrend, with buyers in control; catalysts 79th: open-market insider buys in 90 days 36, analysts have raised their average price target by 2.4% since the prior reading; weakest is setup 35th: day-to-day price swings are unusually wide versus its own recent history (wider than about 97% of the past ~6 months). Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
In this list since 18 Aug 2026 — currently 2nd in the list (3 days)
- Entered 18 Aug 2026: first selection for this list at rank 3, score 62.9.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, AMGN's dividend was covered by reported results (earnings payout 66%, free-cash-flow payout 63%). This describes past coverage, not a forecast.
- Earnings payout66% dividends / net income
- Free-cash-flow payout63% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Amgen looks technically
Amgen (AMGN) is trading 24.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 190 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 45, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 73, in overbought territory (above 70). It made a new 20-day high about 3 trading days ago. It is 0.9% below its all-time high.
Trend
8
| Distance from the 200-day | it is trading 24.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +24.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $378.86 | $378.86 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $352.10 | $352.10 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 24 calendar days ago — the swings before that are what the structure reading is measured on | 24 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 375.25. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 190 trading days ago — a "golden cross", a bullish long-term signal | 190 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 45, with buyers in control | 45.1 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 73, in overbought territory (above 70) | 73.5 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($376.02 to $443.19) — its "stochastic" reading is 94 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 94.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 21 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $443.19 | $443.19 |
|---|---|---|
| From the 52-week high | it is 0.9% below its 52-week high (its highest price of the past year) | -0.9% |
| Above the 52-week low | it is 62.9% above its 52-week low (its lowest price of the past year) | +62.9% |
| Below the 52-week high | it is at or near its highest point of the past year | 0.9% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $443.19 (set on 2026-08-19) | $443.19 |
| Given back of the 52-week move | over the past year its closes ranged ($271.18 to $442.36), and it has given back essentially none of its rise from last year’s low — 2% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $331.09 to $336.57. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 1.8% |
| From the all-time high | it is 0.9% below its all-time high | -0.9% |
| Nearest price level | it is trading 14.0% above a support level at $377.69 — a price it turned at twice since 2026-03-11, most recently on 2026-07-07. Since 2024-08-21 it has 10 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -14.0% |
| All-time low | its lowest closing price on record is $11.22 (set on 1997-10-23) | $11.22 |
| Above the all-time low | it is 3816.0% above its all-time low | +3,816% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 97% of the past ~6 months) | 97th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $10.97 between its high and its low — about 2.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $10.97 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $369.78 and $446.53 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $369.78 – $408.16 – $446.53 |
| Typical daily range (% of price) | its price moves about 2.5% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.5% |
| Stretch from the 200-day average | it is trading 8.0 daily ranges above its 200-day average price (24.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 8.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.84× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 2.4% since the prior reading | +2.4% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.5% |
|---|---|---|
| Gap filled | a 2.0% gap down opened on 2026-07-30 has been "filled" 16 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 16 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 17.6 percentage points (the stock gained 20.0% while the market gained 2.3%) | +17.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 27.1 percentage points (the stock gained 30.2% while the market gained 3.1%) | +27.1% |
| vs market, 6 months | over the past 6 months this stock beat the market by 6.2 percentage points (the stock gained 17.2% while the market gained 11.1%) | +6.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 28.1 percentage points (the stock gained 48.5% while the market gained 20.5%) | +28.1% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 22% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.7% of the share price. | +22.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 22% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $358.73 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +22.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-08-04 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $416.67 — a volume-weighted average of daily closes over 14 sessions, not a true tick-by-tick VWAP. | +5.4% |
Price levels it has turned at before
AMGN last closed at $439.33 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $377.69 | Support | 14.0% below the last close | turned there twice · 2026-03-11 to 2026-07-07 |
| $357.23 | Support | 18.7% below the last close | turned there six times · 2026-01-27 to 2026-07-15 |
| $342.47 | Support | 22.1% below the last close | turned there 8 times · 2024-09-23 to 2026-05-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $375.25.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $375.98 and $387.60 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Overbought (14-day RSI above 70) · Near the 52-week high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · Analyst price target recently RAISED | Learn: moving average · golden cross · adx · rsi · breakout · all time high
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.47 mean, 1=Strong Buy…5=Strong Sell) — 29 analysts
- Mean price target$388.48 range $230.00 – $457.00; median $395.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AMGN
- Consensus EPS estimate$5.78 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Government price setting and legislative changes to reimbursement (e.g., IRA, OB3) significantly impact pricing, sales, and profitability.","High dependence on competitive intellectual property rights and the timing of market entry of generic or biosimilar competition.","Complex and evolving U.S. government price reporting regulations carry risks of substantial fines, penalties, and required retroactive rebate payments."]
What changed in the latest 10-Q
AI-assisted comparison of AMGN's 10-Q filed 2026-05-01 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references December 31, 2025 as the year-end for the 10-K (vs. December 31, 2024 in older filing)
- Newer filing specifies evaluation period as three months ended March 31, 2026 (vs. nine months ended September 30, 2025)
- Newer filing includes statement that disclosure controls and procedures were effective as of March 31, 2026
- Newer filing includes statement that no changes in internal control over financial reporting materially affected or are reasonably likely to materially affect the company during the fiscal quarter ended March 31, 2026
- Newer filing references Part I—Note 13 and Part IV—Note 20 to consolidated financial statements in the 10-K for year ended December 31, 2025
- Removed:
- Older filing contained a section on 'Market-price-sensitive financial instruments' with specific equity investment risk disclosures including BeOne and Neumora investments
- Older filing contained quantitative disclosure that a 20% decrease in equity investment portfolio would result in losses of approximately $1.5 billion as of September 30, 2025 and $950 million as of December 31, 2024
- Older filing referenced December 31, 2024 as the year-end for the 10-K
- Reworded:
- Item 3 statement changed from 'There were no material changes during the nine months ended September 30, 2025' to 'There were no material changes during the three months ended March 31, 2026'
- Item 3 statement changed from referencing 'Part II, Item 7A...of our Annual Report on Form 10-K for the year ended December 31, 2024' to referencing 'December 31, 2025'
- Older filing stated there were no material changes 'except as related to our market-price sensitive financial instruments disclosed below' whereas newer filing contains no such qualification
- Notes:
- The newer filing is a 10-Q for Q1 2026 (quarter ended March 31, 2026) while the older filing is a 10-Q for Q3 2025 (quarter ended September 30, 2025), so some differences reflect different reporting periods and different underlying 10-K references
- The removal of market-price-sensitive financial instruments disclosure reflects different portfolio composition or risk assessment at different quarter-end dates, not necessarily a policy change
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 6 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 6 sells ($4M) — 3 selling insiders
- Last 90 days0 buys · 6 sells ($4M) — 3 selling insiders
- Last 180 days0 buys · 7 sells ($5M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-13. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AMGN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 27 matched disclosures for AMGN from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding AMGN as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 82,984,127
- Reported value $29,197,965,149
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
AMGN had 13,280,607 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
AMGN had 2.46% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.16 days to cover at the same settlement.
- Reported short interest (shares) 13,280,607
- Short interest (% of shares outstanding) 2.46%
- Prior settlement (shares) 12,845,008
- Reported change 3.39%
- Days to cover (reported) 5.16
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- AbbVie (ABBV)
- Bristol-Myers Squibb (BMY)
- Johnson & Johnson (JNJ)
- Merck & Co. (MRK)
- Pfizer (PFE)
- Gilead Sciences (GILD)
- Regeneron Pharmaceuticals (REGN)
- Eli Lilly (LLY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AMGN vs…
Amgen is found in…
AMGN ranks in…
AMGN shows up in…
Frequently asked questions
What does Amgen (AMGN) do?
Amgen is a global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics for serious illnesses. Its diverse portfolio includes treatments for inflammation, oncology/hematology, bone health, cardiovascular disease, and nephrology. The company is also active in the development of biosimilars and innovative small molecule and biologic therapies.
What sector is Amgen (AMGN) in?
Amgen (AMGN) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Does AMGN pay a dividend?
Yes — Amgen (AMGN) pays a dividend, with an indicated yield of about 3.21% and at least 5 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are Amgen's (AMGN) competitors?
Notable peers of Amgen (AMGN) include AbbVie, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co. and Pfizer. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in AMGN?
Yes — we hold 27 matched STOCK Act disclosures for AMGN from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Amgen (AMGN) overbought or oversold right now?
Amgen (AMGN) is currently in overbought territory (its 14-day RSI is 73, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AMGN come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.